Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › clesrovimab

clesrovimab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of clesrovimab

4 trials tracked of clesrovimab: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 38 citations.

4Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 2
  1. Phase 3 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Completed · 38 cited
  2. Phase 3 Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Completed · 11 cited
  3. Phase 2 Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) Completed
  4. Phase 2 Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CDC recommends clesrovimab for preventing severe RSV lower respiratory infections in infants
Allergy & Immunology
CDC recommends clesrovimab for preventing severe RSV lower respiratory infections in infants CDC recommends new antibody to protect infants from severe RSV
The CDC has issued a recommendation for the use of clesrovimab to prevent severe respiratory syncytial virus-associated lower respiratory tr…
The CDC now recommends a new antibody to help protect infants from severe respiratory syncytial virus infections.
CDC Apr 3, 2026